Esperion's Oral Bempedoic Acid Passes First Phase III Cholesterol Test
Executive Summary
'Study 4' results may support a label claim related to reducing inflammation – measured through the high sensitivity C-reactive protein (hsCRP) marker – down the line, the company told investors.
You may also be interested in...
Esperion Posts Positive Phase III Bempedoic Acid Results, But Future Fixed-Dose Data Are Key
Esperion reported positive results from the third of five Phase III studies expected to read out this year, but data for a bempedoic acid/ezetimibe fixed-dose combo expected in August may be the key to the drug's commercial future.
Deaths In Esperion's Long-Term Bempedoic Acid Trial Spur Fears Of Commercial Delay
On top of concerns about safety, which could present regulatory hurdles, bempedoic acid is likely to face a tougher competitive environment after the decline in PCSK9 inhibitor pricing.
PCSK9 Add-On Study Helps Esperion Cover All The Bases With Bempedoic Acid
Phase II data on use with PCSK9 injectable support bempedoic acid's safety and efficacy profile as an add-on therapy in high cholesterol.